title: Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.
abstract: Platelet derived growth factor-α (PDGFR-α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR-α expression by immunohistochemistry and fluorescence in situ hybridization (FISH) to assess for FIP1L1-PDGFR-α fusion and/or PDGFR-α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis of PDGFR-α by immunohistochemistry and three of these patients' tumors expressed PDGFR-α. Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR-α expression was not required for study entry.
authors.affiliation: Medical Oncology, Dana-Farber Cancer Institute , Boston, MA , USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Jacobsen
authors.forename: Olga
authors.initials: O
authors.lastname: Pozdnyakova
authors.forename: Robert
authors.initials: R
authors.lastname: Redd
authors.forename: David C
authors.initials: DC
authors.lastname: Fisher
authors.forename: David M
authors.initials: DM
authors.lastname: Dorfman
authors.forename: Paola
authors.initials: P
authors.lastname: Dal Cin
authors.forename: Ann
authors.initials: A
authors.lastname: LaCasce
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
authors.forename: Ephraim
authors.initials: E
authors.lastname: Hochberg
authors.forename: Gregory
authors.initials: G
authors.lastname: Cote
authors.forename: Ali
authors.initials: A
authors.lastname: Shahsafaei
authors.forename: Donna
authors.initials: D
authors.lastname: Neuberg
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Freedman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics / Q000378:metabolism; D012008:Recurrence; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha
keywords: Lymphoma; PDGFR-α; imatinib